Search research articles
Contact Us
Filters
Showing results (41-50 of 76) with videos related to
Page
of 8
Sort By:
Annals of Hematology
|
July 23, 2022
Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis
Shai Shimony, Jonathan Canaani, Eitan Kugler, et al.
Journal of Thrombosis and Haemostasis : JTH
|
February 19, 2021
Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors
Oded Icht, Naama Darzi, Shai Shimony, et al.
British Journal of Haematology
|
November 29, 2024
Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM
Iuliana Vaxman, Shaji Kumar, Inbar Cohen, et al.
Leukemia
|
January 4, 2024
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols
Yannis K Valtis, Yael Flamand, Shai Shimony, et al.
European Journal of Haematology
|
February 9, 2026
Obinutuzumab Maintenance in Follicular Lymphoma Is Associated With Better Progression Free Survival and Comparable Toxicity
Renana Robinson, Tamar Berger, Tzippy Shochat, et al.
Blood Advances
|
November 15, 2024
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
Marlise R Luskin, Shai Shimony, Julia Keating, et al.
Blood Advances
|
May 10, 2023
FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
Shai Shimony, Geoffrey Fell, Evan C Chen, et al.
Blood Advances
|
July 11, 2023
Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
Shai Shimony, Yael Flamand, Yannis K Valtis, et al.
Leukemia & Lymphoma
|
October 26, 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
Jan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Leukemia Research
|
September 15, 2022
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax
Jan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 76) with videos related to
Sort By:
Page
of 8
Annals of Hematology
|
July 23, 2022
Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis
Shai Shimony, Jonathan Canaani, Eitan Kugler, et al.
Journal of Thrombosis and Haemostasis : JTH
|
February 19, 2021
Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors
Oded Icht, Naama Darzi, Shai Shimony, et al.
British Journal of Haematology
|
November 29, 2024
Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM
Iuliana Vaxman, Shaji Kumar, Inbar Cohen, et al.
Leukemia
|
January 4, 2024
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols
Yannis K Valtis, Yael Flamand, Shai Shimony, et al.
European Journal of Haematology
|
February 9, 2026
Obinutuzumab Maintenance in Follicular Lymphoma Is Associated With Better Progression Free Survival and Comparable Toxicity
Renana Robinson, Tamar Berger, Tzippy Shochat, et al.
Blood Advances
|
November 15, 2024
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
Marlise R Luskin, Shai Shimony, Julia Keating, et al.
Blood Advances
|
May 10, 2023
FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
Shai Shimony, Geoffrey Fell, Evan C Chen, et al.
Blood Advances
|
July 11, 2023
Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
Shai Shimony, Yael Flamand, Yannis K Valtis, et al.
Leukemia & Lymphoma
|
October 26, 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
Jan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Leukemia Research
|
September 15, 2022
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax
Jan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Page
of 8